These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23377664)

  • 1. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
    Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
    J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
    Jouanneau E; Poujol D; Gulia S; Le Mercier I; Blay JY; Belin MF; Puisieux I
    Cancer Immunol Immunother; 2006 Mar; 55(3):254-67. PubMed ID: 16133115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
    Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ
    Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
    Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
    BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
    Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW
    Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
    Rudnick JD; Sarmiento JM; Uy B; Nuno M; Wheeler CJ; Mazer MJ; Wang H; Hu JL; Chu RM; Phuphanich S; Black KL; Yu JS
    J Clin Neurosci; 2020 Apr; 74():187-193. PubMed ID: 32169363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
    Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
    J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
    Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
    Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
    Yamanaka R; Abe T; Yajima N; Tsuchiya N; Homma J; Kobayashi T; Narita M; Takahashi M; Tanaka R
    Br J Cancer; 2003 Oct; 89(7):1172-9. PubMed ID: 14520441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
    Zhu X; Lu C; Xiao B; Qiao J; Sun Y
    J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.
    Lasky JL; Panosyan EH; Plant A; Davidson T; Yong WH; Prins RM; Liau LM; Moore TB
    Anticancer Res; 2013 May; 33(5):2047-56. PubMed ID: 23645755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ dendritic cell vaccination for the treatment of glioma and literature review.
    Li M; Han S; Shi X
    Tumour Biol; 2016 Feb; 37(2):1797-801. PubMed ID: 26318301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
    Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK
    J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis.
    Cao JX; Zhang XY; Liu JL; Li D; Li JL; Liu YS; Wang M; Xu BL; Wang HB; Wang ZX
    PLoS One; 2014; 9(9):e107173. PubMed ID: 25215607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
    Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
    Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
    Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
    Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
    Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
    Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
    Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
    Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.